Initial safety assessment of the endoscopically injected oncolytic virus OBP-301 in medically inoperable esophageal cancer: NRG-GI007.
Geoffrey Y. Ku(Memorial Sloan Kettering Cancer Center), Theodore S. Hong(Massachusetts General Hospital), Rutika Mehta(Cornell University), Jennifer Moughan(NRG Oncology), Terence M. Williams(City Of Hope National Medical Center), Eric D. Miller(The Ohio State University), Makoto Nishimura(Memorial Sloan Kettering Cancer Center), Adam D. Yock(Vanderbilt University Medical Center), Samuel J. Klempner(Broad Institute), Prasad S. Adusumilli(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
|Journal of Clinical Investigation|2016|1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914